Updated on 8 September 2014
Catalent will redesign MIL-38 as a therapeutic antibody
Singapore: Australian biotechnology company Minomic International has collaborated with US partner to develop a potential new therapy for prostate cancer based on its existing antibody screening technology.
The company has made an agreement with Catalent Pharma Solutions to develop Minomic's MIL-38 antibody drug conjugate (ADC) as a therapeutic product, rather than a screening target.
Minomic currently uses this antibody target in a novel prostate cancer screening technology known as MiStat, which is expected to be launched globally in 2015.
Under the terms of this latest agreement, Catalent will redesign MIL-38 as a therapeutic antibody using its proprietary GPEx technology for a clinical study, with production to be scaled up on successful outcome.
Dr Brad Walsh, CEO, Minomic said pre-clinical trials of the MIL-38 antibody target as a therapeutic had been extremely promising.